Strategic snapshot
The whole competitive picture in six roles — who sets the benchmark, who threatens the formula, who anchors the price, and where the white space sits.
IM8
$183 Beckham Stack — the premium U.S. system to out-execute.
The Longevity Store
24 ingredients with real overlap at a far lower price. No confirmed U.S. storefront.
AG1
$79/month is the mental reference every $159 conversation starts from.
Thorne / Timeline
NSF portfolio trust and proprietary clinical IP — two routes to credible premium.
Blueprint / Immortals
The only set member with a real connected platform — and proof of its cost.
Performance + healthspan + connected protocol
One sachet, meaningful doses, and a protocol that tracks adherence over time.
Why dosiis is different
Meaningful formula
Performance + healthspan
One ritual
Consolidation and convenience
Connected protocol
Tracking + subscription + longitudinal relationship
A strategic framing, not a proven claim.
Launch-market strategy: Americas first
Pricing is benchmarked in U.S. dollars against U.S. subscription behaviour — not European VAT-inclusive shelf prices.
United States
Primary launch and brand-building market
Price, claims, channels, creators, athlete partnerships and DTC economics are all designed around the U.S. first
Canada · Mexico · Panama
Adjacent premium markets, separate launches
Health Canada NPN licensing, COFEPRIS import and advertising review, and Panamanian sanitary registration each gate commercialisation
European Union
Future strategic market, not the current formulation constraint
Assess reformulation later; build brand equity without forcing the launch product into the strictest market prematurely
- IM8, AG1, Thorne, Blueprint and Timeline become the highest-priority commercial benchmarks.
- The Longevity Store and AVEA remain international reference points with less weight on launch pricing.
- U.S. structure/function claims offer a different communication framework from the EU; disease claims remain prohibited either way.
- Canada, Mexico and Panama cannot be treated as ship-to extensions of the U.S. launch.
- Optimise the current formula for the launch markets first; evaluate an EU-compatible variant after U.S. product-market fit.
Formula architecture
Preliminary NAIE formulation (code 783 B). Explore the five clusters that make up one ~21g daily sachet.
Performance
preliminaryStrength, power, blood-flow and cellular energy — the axis almost every longevity-framed competitor leaves open.
Preliminary NAIE formulation (code 783 B). Plus flavouring, bulking, sweetening and anti-caking excipients as technically required. Not a final label — subject to pilot trials, stability testing, regulatory review and final sourcing.
- Manufactured by NAIE S.A. (Switzerland), internal code 783 B.
- Quotations: $50.00/box at 2,000 boxes; $48.30 at 3,000; $46.20 at 5,000.
- ~$30/box is raw materials — NR the largest driver (~$12.5/box), then acacia fibre (~$3.5), AC-11 (~$3.0) and CreHytine (~$2.8).
- CreHytine MOQ (~1,600kg) far exceeds what a 2,000–5,000-box run consumes (320–800kg) — a working-capital commitment that never appears in per-box COGS.
- Three-stage rollout: technical pilot batch (not for sale) → limited commercial validation run → full commercial production.
Ingredient hierarchy
The decision-useful comparison is not total ingredient count but whether a strategically relevant active appears at a disclosed, meaningful dose.
Core
Establish the hybrid thesis. Losing any of these would materially weaken the positioning.
Performance
Reinforce the performance case, but the thesis survives if one or two are trimmed for taste or cost.
Longevity signatures
Differentiators, not anchors. Each remains subject to cost, MOQ, NDI status, evidence, sensory impact and readability.
Formula complexity is not automatically product superiority.
Category structure and white space
Four clusters, plus one distinction that cuts across all of them: product-only versus connected protocol.
Daily all-in-one nutrition
Simplification and broad coverage, not advanced athletic performance or narrow longevity mechanisms.
Longevity systems
Healthy-aging narratives through hallmark coverage, founder protocol, or proprietary single-ingredient science.
Performance / athlete-led
Trust through athletic relevance, sport testing, professional-team adoption and performance outcomes.
Hybrid performance + longevity
The clearest U.S. proof that the market pays for feel-better-now plus long-term health as one system.
Primary U.S. ideal customer profile
A launch hypothesis to validate through the 90-day consumer research workstream — the initial customer to design for, not the eventual addressable market.
- 30–50 years old
- Skews higher disposable income
- Urban / affluent suburban
- Professionally ambitious, health-conscious
- Exercises 3–6× per week
- Already buys creatine, electrolytes or longevity products
- Spends meaningfully on health optimisation
- Comfortable with subscription; digitally engaged
- Apple Watch, WHOOP, Oura, Garmin, Strava
- Premium gym or boutique studio
- Follows longevity and functional-medicine content
- Quantifies health but cannot connect supplements to it
- ~$100–250+/month on supplements today
- Refuses to choose between performing now and aging well
- Values evidence, transparency and time efficiency
- Secondary segment: 40–60 affluent healthy-aging
The strongest early customer already quantifies their health closely but has no integrated way to connect their supplement routine to the rest of their tracked behaviour.
Strategic positioning maps
Four readings of the same competitive set. Switch maps to watch each brand move; hover or click a bubble for its price, category and strategic role.
Most brands are strong on performance or longevity.
Almost every competitor is stronger on one axis than the other. No other brand in the set targets the extreme upper-right the way the preliminary dosiis formula does — the apparent white space, and the hardest formulation and messaging problem to execute well.
Almost every competitor is stronger on one axis than the other. No other brand in the set targets the extreme upper-right the way the preliminary dosiis formula does — the apparent white space, and the hardest formulation and messaging problem to execute well. Dashed outlines mark international references without confirmed U.S. availability.
Compare brands side by side
Select up to four brands. The key distinction is competitive role, not just price.
IM8
in market- David Beckham as founder-level brand authority
- Named scientific advisory board
- NSF Certified for Sport
- Registered finished-product RCT
- Large marketing and distribution scale
dosiis
leading hypothesisCan dosiis deliver enough trust and product quality to make one $159 daily ritual feel more valuable and more convenient than a $183 two-product system?
Intensity bars are analyst judgment consistent with the positioning maps in this report — a strategic framework, not a validated scientific index. Prices are the point-in-time snapshots verified for this pass.
Competitor explorer
Nine benchmarks. Open any card for position, trust engine, lesson and implication.
Digital competitive landscape
The dimension most competitive reports skip: does the brand offer anything beyond a transactional purchase?
| Capability | IM8 | The Longevity Store | SILA | AG1 | Thorne | Blueprint / Immortals | NOVOS | Timeline | AVEA | dosiis |
|---|---|---|---|---|---|---|---|---|---|---|
| Subscription | ||||||||||
| App | ||||||||||
| Biomarkers | ||||||||||
| Wearables | ||||||||||
| Adherence | ||||||||||
| Health dashboard | ||||||||||
| AI / personalization | ||||||||||
| Connected protocol | ||||||||||
| lead | target |
Hover a brand column to read what was identified in this research pass. Where no capability was identified, that is stated explicitly — it is not the same claim as 'the brand does not offer this'.
U.S. pricing architecture
AG1 at $79/mo anchors the mainstream premium daily ritual; Timeline at $89/mo demonstrates specialist clinical premium; Blueprint Easy Stack is $98; IM8's Beckham Stack starts at $183.
Price calculator
Industrial product margin only — before fulfillment, payment fees, discounting, shipping, returns, CAC and excess-MOQ carrying cost. Do not treat manufacturing-COGS-based margin as true gross margin at any price point.
Replacement value and convenience economics
A stronger consumer argument than ingredient count, because the target buyer already understands the inconvenience and cumulative cost of a full supplement shelf.
Reference points from the source register. The complete conservative core basket lands at ~$180–185 per month across 5 products and 5 daily actions.
Even the conservative, well-sourced core alone (~$180–185/month) already exceeds the $159 hypothesis. The proposition is consolidation, convenience and formulation coherence — not simple ingredient arbitrage.
The consumer message should not be “18 supplements in one.” A more defensible proposition is that one daily sachet consolidates the core of a premium performance, hydration, gut and healthy-aging routine that would otherwise require several products.
dosiis protocol — connected product experience
Three-layer architecture
dosiis formula
Physical daily productdosiis protocol
Consumer relationshipdosiis data
Connected health contextdosiis ≠ sachet only.
Interface concept
Illustrative concept. The platform is not live.
Evidence at the level of individual actives — the launch standard, and insufficient on its own at $179.
Dashed steps are the dosiis target direction, not achieved milestones. At $179, “science-backed ingredients” is insufficient as the sole proof layer.
Recommended authority architecture
Not one very expensive global celebrity. The stronger early-stage configuration is three complementary voices validating the three pillars U.S. consumers need to believe: use, safety and science, performance relevance.
The public description must match the actual relationship — founder, investor, advisor and ambassador are not interchangeable.
Regulatory and market-entry architecture
Four jurisdictions, four separate gates — plus one entirely separate track for health data.
United States
Design marketFDA permits structure/function claims within the applicable framework; disease-treatment claims are not appropriate. CGMP under 21 CFR Part 111 applies. Build a claims matrix before packaging and paid creative lock: classify every claim, maintain substantiation files, and confirm NDI/ingredient status for each exact source — with particular weight on NR, spermidine, AC-11, ergothioneine, PQQ and Ca-AKG.
Canada
Licensing-gatedA separate launch project, not an extension of U.S. fulfillment. Health Canada requires a product licence and an eight-digit NPN covering medicinal ingredients, source, potency, non-medicinal ingredients and recommended use — materially affecting timing and permitted claims.
Mexico
Import, label, advertising gateCommercially attractive, but activate only after local review of classification, ingredients, dosage, Spanish labeling, importer responsibilities and advertising. COFEPRIS requires prior sanitary import procedures and regulates advertising.
Panama
Registration before commercializationSanitary registration requires formula, finished-product specifications, analysis certificates, free-sale certificate, GMP documentation and labels. A local partner should determine the exact classification pathway.
Europe
Future optionSeveral components and/or intended uses may require a different pathway. Preserve a U.S.-first formula if it is commercially and technically superior, then evaluate an EU-compatible variant after product-market fit.
Health-data privacy
Separate trackThe protocol will process sensitive health information. HIPAA applicability, expanding U.S. state privacy statutes, Canadian/Mexican/Panamanian frameworks and Apple/WHOOP/Oura/Garmin platform data-use rules each require confirmation. Plan a specialist privacy review alongside the digital MVP, not after it.
Risks and vulnerabilities
Plotted by execution sensitivity against strategic impact. Not every risk is equally urgent.
Click any risk to read why it matters and its mitigation. Filled orange markers are the highest-priority risks.
Strategic recommendations
“Performance today. Healthspan tomorrow.” Supporting systems sit underneath the sentence, not compete with it.
5g creatine, meaningful electrolytes, 5g fibre, 300mg NR and the highest-signal longevity signatures — subject to pilot and regulatory review.
$149 as first-cohort entry, $179 as an earned premium — and the physical product must justify it independent of the digital layer.
Do not scale a technically impressive formula that consumers dislike taking every day.
Independent batch testing, accessible COAs, sport certification, and the athlete + physician + scientist triangle.
Equivalent-dose reputable products; must clear advertising-substantiation review before external use.
Account, subscription and adherence at launch; Apple Health at ~90 days; wearables by observed usage; insights post-PMF.
Privacy-by-design, explicit consent, data minimisation, clear separation between wellness tracking and medical claims.
Never describe observed correlations as causation, internally or externally.
Explain standards, sourcing and testing concretely.
Local partners and product gates for each — not a translated U.S. website.
Do not compromise U.S. product-market fit to force one global formula prematurely.
Blueprint's platform investment and any international entrant's U.S. launch are the two highest-priority signals.
90-day decision agenda
Ten workstreams across four horizons. Select any initiative for its deliverable and the decision it unlocks.
What must be proven before scale
Five product gates in sequence, plus one separate platform-scale gate.
No single gate is sufficient on its own — a technically excellent product with no trust, or a well-liked product with poor unit economics, is not ready to scale.
The dosiis investment thesis
Source register and data caveats
Primary sources re-checked for the U.S.-first strategic snapshot.
- dosiis formula, NAIE quotes, ingredient-cost breakdown, MOQ examples and the three-stage manufacturing strategy are founder-supplied internal inputs, not independently validated with NAIE in this pass.
- The formula is preliminary. Pilot trials, sourcing and regulatory review can change ingredient selection and dose.
- Prices are snapshots and may change by promotion, region, subscription length, currency and tax. Re-verify immediately before investor or public use.
- International competitor prices (TLS in EUR, AVEA in GBP) are strategic anchors, not confirmed U.S. price points.
- Formula Density and Replacement Value are strategic frameworks, not efficacy scores.
- Competitor health and science statements are described as brand claims unless independently supported; inclusion is not endorsement.
- This report is commercial and strategic analysis and does not replace legal, regulatory, medical or tax advice.
Prepared as a strategic working document for the dosiis founders and prospective investors. Research snapshot: current U.S. market view.